Close Menu

NEW YORK – Bio-Rad Laboratories reported Thursday after the close of the market that its second quarter revenues fell 6 percent year over year, primarily due to COVID-19 pandemic-related slowdowns.

For the three months ended June 30, 2020, Bio-Rad reported revenues of $536.9 million compared to $572.6 million a year ago, besting analysts' average estimate of $517.1 million.

On a currency-neutral basis, Q2 revenues decreased about 4 percent, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.